Compare Cytokinetics Inc (CYTK) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Cytokinetics Inc trades at $82.32 (market cap $11.12B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $242.66 (market cap $44.01B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 4× Cytokinetics Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock nearer its low. Which is the better fit depends on your goals.
| CYTK | TTWO | |
|---|---|---|
Market Cap | $11.12B | $44.01B |
Sector | Technology | Media |
52-Week High | $87.26 | $262.29 |
52-Week Low | $33.23 | $189.69 |
Enterprise Value | $11.59B | $44.98B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Take-Two Interactive (TTWO) trades at $244.10, up 0.37% on the day, with a bullish technical outlook supported by moving averages and ADX signals. The stock has consistently beaten earnings expectations in recent quarters, though it reported a net loss of -$4.48 billion in FY2025. Sentiment is highly positive due to strong pre-orders for Grand Theft Auto VI, priced at $79.99 with a November 2026 launch, driving analyst optimism.
The outlook is driven by GTA VI's monetization potential, with a consensus price target of $302.50 implying 24% upside. Risks include high debt levels, negative profitability, and execution challenges. Institutional confidence remains strong with 79% buy ratings, but investors should monitor cash flow trends and competitive pressures in the gaming sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
